GlassScriptPhysician profile
Louise M Convery
NPI 1699728287
$8,478.79
in general payments reported to CMS, 2019-2025
37 companies · $604 in 2025
The $604 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,525 · 2020: $1,379 · 2021: $1,806 · 2022: $1,186 · 2023: $1,025 · 2024: $953 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,401 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,401.21 |
| Education | $181.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,209.62 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Pfizer INC. | $983.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $923.29 | 2019-2025 | Farxiga, Xigduo, Airsupra |
| Janssen Pharmaceuticals, INC | $922.64 | 2019-2024 | Xarelto |
| Abbvie INC. | $602.60 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Lilly USA, LLC | $519.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $383.65 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $306.89 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $281.66 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $239.22 | 2023-2024 | Uptravi, Opsumit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.06 | 2019-2024 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $224.45 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $186.51 | 2019-2025 | Capvaxive, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $181.86 | 2020-2021 | |
| Allergan, INC. | $155.55 | 2019-2020 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louise Convery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.